Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma Journal Article


Authors: Dang, N. H.; Ogura, M.; Castaigne, S.; Fayad, L. E.; Jerkeman, M.; Radford, J.; Pezzutto, A.; Bondarenko, I.; Stewart, D. A.; Shnaidman, M.; Sullivan, S.; Vandendries, E.; Tobinai, K.; Ramchandren, R.; Hamlin, P. A.; Giné, E.; Ando, K.
Article Title: Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Keywords: adult; controlled study; protein expression; treatment response; major clinical study; overall survival; constipation; fatigue; neutropenia; cancer recurrence; diarrhea; drug efficacy; drug safety; drug withdrawal; side effect; gemcitabine; rituximab; letter; progression free survival; anemia; leukopenia; nausea; randomized controlled trial; thrombocytopenia; vomiting; cohort analysis; bendamustine; alanine aminotransferase blood level; aspartate aminotransferase blood level; coughing; febrile neutropenia; fever; gamma glutamyl transferase blood level; lymphocytopenia; pneumonia; alanine aminotransferase; alkaline phosphatase; aspartate aminotransferase; nonhodgkin lymphoma; alkaline phosphatase blood level; hyperbilirubinemia; phase 3 clinical trial; gamma glutamyltransferase; treatment withdrawal; cd22 antigen; decreased appetite; septicemia; inotuzumab ozogamicin; diffuse large b cell lymphoma; antibody-drug conjugate; human; priority journal; b-cell non-hodgkin lymphoma; cd22+
Journal Title: British Journal of Haematology
Volume: 182
Issue: 4
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2018-08-01
Start Page: 583
End Page: 586
Language: English
DOI: 10.1111/bjh.14820
PROVIDER: scopus
PUBMED: 28677896
PMCID: PMC6200343
DOI/URL:
Notes: Letter -- Export Date: 4 September 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Paul Hamlin
    277 Hamlin